Immunovant stock falls after lupus drug trial misses goal

2 sources ·3 articles ·13h ago Immunovant

2 outlets - including Investing and Biopharmadive - are covering this story. Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

Covered by 2 outlets

Investing 2 Biopharmadive 1

All coverage · 3 articles

BioPharma Dive ·13h ago

Lilly’s latest China drug deal; Immunovant’s setback in lupus

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

Investing.com Canada ·Sep 23, 11:28 UTC